FENFURO

Name: FENFURO
SKU: FEN
Availability: InStock

$19.00 – $57.00

FENFURO™ is a proprietary product derived from Fenugreek seeds (Trigonella Foenum Graecum) by an innovative process. It is a group of furostanolic saponins that help to maintain healthy blood glucose levels. FENFURO contains a rich variety of saponins and flavonoids. All of these substances are known to play valuable role in maintaining a stable Glucose levels.

Fenfuro is supported by 7 international patents and has also been clinically evaluated on 462 diabetic patients. The clinical studies have been published in well-known international journals and have won awards in many international conferences.

SKU: FEN Categories: Ayurvedic, Herbal

Helps to maintain healthy blood glucose levels through Herbs.

100% natural and innovative
Extracted naturally from Fenugreek seeds
It is a single herb extract without additives and excipients
Suitable to maintain blood glucose level
Supported by 7 international patents
Clinically Evaluated on 462 patients

No known side effects
Halal and Kosher certified
Mitigates the risk of unhealthy blood glucose level
Easily digested and readily absorbed
Natural Supplement
30 convenient capsules to allow you to take anywhere with you

Clinical Evaluation of Fenugreek Seed Extract in 2 58 Patients with Type- 2 Diabetes : An Add-On Study at Two Medical Colleges in India.

Efficacy Conclusions

A significant decrease in HbA1c levels was observed as compared to respective baseline value and as compared to placebo after weeks.
Fenfuro caused significant reduction in the fasting blood sugar levels.
Fenfuro caused significant reduction in the post prandial (PP) blood sugar levels as compared to Placebo group as well as compared to respective baseline value.
83% of the patients reported decrease in fasting sugar levels in Fenfuro treated group as compared to 62% in Placebo treated group.
89% of the patients reported decrease in PP sugar levels in Fenfuro treated group as compared to 72% of the patients in the Placebo treated group.
48.8% of the patients reported reduced dosage of anti diabetic therapy in Fenfuro treated group, where as 18.05% of the patients reported reduced dosage of anti diabetic therapy in Placebo treated group.
Fasting glucose: The mean fasting glucose levels were significantly decreased in FENFURO-treated patients, whereas these levels increased in on-going anti-diabetic therapy-treated patients. FENFURO caused 38.26% decrease in fasting glucose levels on completion of the treatment. Such decrease in fasting glucose levels was observed in 95.2% of the study population on completion of the treatment with FENFURO.
Post-prandial (PP) glucose: FENFURO caused significant decrease in PP glucose levels on completion of the treatment as compared to the on-going anti-diabetic therapy-treated population. The decrease in mean PP glucose levels were up to 44.04% in the FENFURO-treated study population on completion of the treatment. As observed on completion of the treatment with FENFURO, 88.10% of study population shown to have decrease in PP glucose levels.
Glycated hemoglobin (HbA1c): FENFURO treatment resulted in normalizing the mean HbA1c levels of the study population. The HbA1c levels decreased significantly in the study population of both groups on completion of the treatment. Mean HbA1c levels decreased up to 34.70% in
FENFURO-treated group whereas on-going anti- diabetic therapy caused 21.51% decrease in HbA1c levels. These HbA1c levels came to normal range (Good control range – 4.5-6.3%) in FENFURO-treated study population whereas they were still abnormal (Poor control levels – 7.6%) in on-going anti-diabetic therapy treated population till 12 weeks of treatment.

Safety Conclusions

No significant change in serum SGOT, SGPT & ALP activities was observed, indicating investigational product (Fenfuro-fenugreek seed extract) was safe for liver functioning.
No significant change in blood urea nitrogen and creatinine levels was observed indicating investigational product (Fenfuro-fenugreek seed extract) was safe for kidney functioning.
No significant change in hematological parameters was observed.
Keeping hematological and biochemical results in view, investigational product was safe for consumption.
No significant change in the liver function tests (serum glutamic-oxaloacetic transaminase, serum glutamic-pyruvic transaminase, alkaline phosphates activities and serum bilirubin levels) was observed on completion of the treatment.
No significant change in the serum urea levels and creatinine levels was observed on completion of the treatment.
No significant change in the hematological parameters was observed on completion of the treatment.

Unique features of FENFURO^TM

FENFURO^TM is a first of its kind product derived from single herb with proven results for maintaining blood sugar levels.
Scientific Research supports the non-toxicity of the product.
Scientifically processed without affecting the chemical properties of the active ingredient to give maximum benefit.

*Complete clinical data available on request

Innovative product FENFURO is now protected with following patents :

Recommended Dosage

TYPE-2 DIABETES:

PATIENTS ON OHA AND INSULIN – Add FENFURO™ to the existing medicinal regimen. Recommended dosage of FENFURO™ for better and fast results is one capsule three times a day (before meal). Patient should monitor FBS & PPBS level from 7th-9th day onwards. If hypoglycemic symptoms are noticed, insulin intake can be tapered depending upon level of FBS & PPBS in consultation with your physician.
FENFURO™ dosage of three capsules is to be continued till the time insulin is no longer required. After this two capsules of FENFURO™ (one in the morning and one in the evening before meal) have to be taken with other OHA till HbA1c <7%. Once HbA1c <7% is achieved, dosage of OHA to be adjusted in consultation with your physician.
PATIENTS TAKING MULTI MOLECULE OHA – Add FENFURO™ to existing medicinal regimen. Recommended dosage of FENFURO™ for better and fast results is one capsule twice a day (one in the morning and one in the evening before meal) till HbA1c <7%. Once HbA1c <7% is achieved, dosage of OHA is to be adjusted in consultation with your physician.

TYPE-1 DIABETES:

If C-peptide is very low, FENFURO™ can be added to the existing medicinal regimen for three months regularly. Recommended dosage of FENFURO™ is three times a day (with meal). Patient should monitor FBS & PPBS level from 7th-9th day onwards. If hypoglycemic symptoms are noticed insulin intake can be tapered depending upon level of FBS & PPBS in consultation with your physician. After three months if any improvement is noticed in C-peptide level, patient can continue taking FENFURO™ otherwise FENFURO™ can be withdrawn.

If C-peptide is normal, probably it is MODY (Maturity-onset diabetes of the young) case & FENFURO™ can help to regenerate newer insulin receptor sites & thereby insulin dosage can be reduced and diabetic complication can be controlled by reducing hyperinsulinemia. Recommended dosage of FENFURO™ is three times a day (with meal). Patient should monitor FBS & PPBS level from 7th-9th day onwards. If hypoglycemic symptoms are noticed insulin intake can be tapered depending upon level of FBS & PPBS in consultation with your physician.

Reviews

There are no reviews yet.

Only logged in customers who have purchased this product may leave a review.

FENFURO

Helps to maintain healthy blood glucose levels through Herbs.